Apr 29, 2020 9:15 am EDT New Capricor Data Reports 100 Percent Survival in Critical COVID-19 Patients Treated with CAP-1002
Apr 13, 2020 9:00 am EDT Capricor Therapeutics to Host Key Opinion Leader Call on Cardiac Complications of Duchenne Muscular Dystrophy
Apr 03, 2020 8:00 am EDT Capricor Initiates Compassionate Use Program for Severe COVID-19 Patients using CAP-1002, its Novel Cell Therapy
Mar 24, 2020 8:00 am EDT Capricor Therapeutics to Host a Key Opinion Leader Call On Why Exosomes are Uniquely Suited for Vaccine Development
Mar 18, 2020 4:01 pm EDT Capricor Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update
Mar 17, 2020 8:00 am EDT Capricor Therapeutics Announces Strategic Plan for Exosome Platform Technology Products Expansion
Mar 11, 2020 4:30 pm EDT Capricor Therapeutics to Present Fourth Quarter and Full Year 2019 Financial Results and Recent Corporate Update on March 18
Dec 19, 2019 1:14 pm EST Capricor Therapeutics Announces Closing of $5.1 Million Offering Priced At-the-Market
Dec 17, 2019 1:52 pm EST Capricor Therapeutics Announces Pricing of $5.1 Million Offering Priced At-the-Market
Nov 07, 2019 4:00 pm EST Capricor Therapeutics Reports Third Quarter 2019 Financial Results and Provides Recent Corporate Update